Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body.

 

DelveInsight’s “Cardiotoxicity Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some Key Highlights from the Cardiotoxicity Market Report:

• Cardiotoxicity was found in 39.6% of anthracycline-treated patients in a recent study (Sendon et al., 2020).
• Cardiotoxicity also seen in patients who were taking anti-HER2 (43.5%), anthracycline and anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and mediastinal radiotherapy (29.1%). (Sendon et al., 2020).
• Around one-third of cancer patients who receive chemotherapy drugs including trastuzumab (Herceptin) and anthracyclines have heart cell damage (University of Michigan, n.d.).
• Cardiotoxicity pipeline therapies include Annamycin (Moleculin Biotech), Camsirubicin (Monopar Therapeutics), and others.
• Moleculin Biotech, Monopar Therapeutics, among others are the major pharmaceutical companies in the Cardiotoxicity market.

 

To gain more insights request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Cardiotoxicity Epidemiology Segmentation

• Various Cancer Total Incident Cases
• Various Cancer Total Number of Patients taking Chemotherapy
• Cardiotoxicity Total Number of Patients taking Specific Chemotherapy Agents
• Cardiotoxicity Total Number of Patients

 

Cardiotoxicity Treatment Landscape

• Dexrazoxan
• ACE inhibitors
• Beta-blockers
• Diuretics
• Digoxin
• Vasodilators

 

To gain more insights request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Some of the Cardiotoxicity Companies:

• Moleculin Biotech
• Monopar Therapeutics
• And Many Others

 

Cardiotoxicity Pipeline Therapies:

• Annamycin
• Camsirubicin
• And Many Others

 

To gain more insights request sample @ https://www.delveinsight.com/sample-request/cardiotoxicity-market

 

Table of Contents

1.	Report Introduction
2.	Executive Summary of Cardiotoxicity
3.	Cardiotoxicity Market Overview at a Glance
4.	Disease Background and Overview: Cardiotoxicity
5.	Case Reports of Cardiotoxicity
6.	Cardiotoxicity Patient Journey
7.	Cardiotoxicity Epidemiology and Patient Population
8.	Epidemiology of Cardiotoxicity by Countries (2018–2030)
9.	Cardiotoxicity Treatments and Medical Practices
10.	Cardiotoxicity Marketed Therapies
11.	Cardiotoxicity Emerging Therapies
12.	Cardiotoxicity Market Size
13.	7MM: Country-wise Market Analysis
14.	Cardiotoxicity Market Drivers
15.	Cardiotoxicity Market Barriers
16.	SWOT Analysis
17.	KOL Views
18.	Reimbursement and market access
19.	Report Methodology
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cardiotoxicity-market